Results 171 to 180 of about 33,145 (233)

KLS-3021, a multifunctional oncolytic virus, demonstrates potent early-intervention efficacy in preclinical models of prostate-confined and locally advanced prostate cancer. [PDF]

Front Oncol
Seo J, Park K, Lee S, Kang H, Kim J, Lee E, Shin J, Hong SO, Kim S, Kim SJ.   +9 more
europepmc   +1 more source

Oncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation. [PDF]

Oncoimmunology
Tang Y, E Q, Ma L, Li X, Zhang Y, Wang W, Jiang Z, Zhang X, Hou Y, Du J, Zhu Y, Dong H, Xu Y, Tian T, Cheng L, Ma Q, Li J, Zhou G, Huang Y.   +18 more
europepmc   +1 more source

Global landscape of oncolytic virus clinical trials for pancreatic cancer: challenges and opportunities. [PDF]

Int J Surg
Yang Y, Ma Y, Tan J, Huang Z.
europepmc   +1 more source

Oncolytic virus M1 reinvigorates CD8⁺ T-cell immunity against glioblastoma through B-cell-dependent antigen cross-presentation in the spleen. [PDF]

Cell Mol Immunol
Han Y, Guo C, Chen C, Yang W, Li H, He C, Deng J, Chen Z, Liu W, Chen J, Zhong Y, Yan C, Xu C, Liang X, Zhong S, Chen F, Li D, Li C, Hu W, Chen Z, Mou Y, Chen Z, Yan G, Lim M, Zhu W, Sai K.   +25 more
europepmc   +1 more source

IRE1α modulates M1 oncolytic virus sensitivity via ER stress regulation in bladder cancer. [PDF]

Cancer Drug Resist
Hu C, Wei S, Zhu W, Lv B, Li S, Liu B, Yan G, Liu Y.   +7 more
europepmc   +1 more source

Neural stem cell-delivered oncolytic virus via intracerebroventricular administration enhances glioblastoma therapy and immune modulation. [PDF]

J Immunother Cancer
Chai H, Xu H, Jiang S, Zhang T, Chen J, Zhu R, Wang Y, Sun M, Liu B, Wang X, Sun X, Zhang K, Zhou L, Shi ZF.   +13 more
europepmc   +1 more source

IP6K2 mutations as a novel mechanism of resistance to oncolytic virus therapy. [PDF]

J Transl Med
Huang Z, Zhao X, Jiang Z, Qiu X, Sun X, Wang D, Zhang H, Chen Q, Tan R, Shen Y.   +9 more
europepmc   +1 more source

Identifying gene expression signatures of oncolytic virus response in patient-derived pancreatic ductal adenocarcinoma organoids. [PDF]

Mol Ther Oncol
Huberts M, Farshadi EA, Mohammad F, Ju J, Stubbs A, Fouchier RAM, van den Hoogen BG.   +6 more
europepmc   +1 more source

In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. [PDF]

Cell Rep Med
Guo C, Gao T, Xue B, Zhang L, Wang S, Xiao R, Kong L, Zhang Y, Xin Q, Cao Y, Gu X, Jiang C, Wu J.   +12 more
europepmc   +1 more source

In vivo neutrophils hitchhiking for tumor targeting and microenvironment regulation boosts oncolytic virus therapy. [PDF]

Cell Rep Med
Zhao X, Huang H, Liu M, Wang P, Song S, Cheng Z, Yu Y, Liu F, Wang Y, Pang Z, Li H, Liu F.   +11 more
europepmc   +1 more source